Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics Inc.

Clear Street analyst Kaveri Pohlman maintained a Hold rating on Akero Therapeutics yesterday and set a price target of $54.00. The company’s shares...

Market Cap	$4.44B	P/E Ratio	N/A
52W High	$58.40	52W Low	$21.34
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	89.0%
Overall Score	60	Value Score	55
Quality Score	--	Technical Score	66

EPS Current Est	$-3.76	EPS Next Est	$-4.16
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AKRO	$54.31	+0.15%	1.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AKRO	$54.31	+0.1%	1.12M
3
4
5
6

AKRO

AKRO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Akero Therapeutics Inc. Data in Excel

Get Akero Therapeutics Inc. Data in Excel